--- a
+++ b/clusters/unpackedclusters/clust_267.txt
@@ -0,0 +1 @@
+Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumabXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranibXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387Xx_NEWLINE_xXPregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparibXx_NEWLINE_xX
\ No newline at end of file